These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23271795)

  • 41. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
    Ezekowitz MD; Connolly S; Parekh A; Reilly PA; Varrone J; Wang S; Oldgren J; Themeles E; Wallentin L; Yusuf S
    Am Heart J; 2009 May; 157(5):805-10, 810.e1-2. PubMed ID: 19376304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
    Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New drug in atrial fibrillation--how does it function in regular health care?].
    Holmström M; Johnsson H; Lärfars G; Malmström R; Hjemdahl P
    Lakartidningen; 2009 Nov 4-12; 106(45):3019-20. PubMed ID: 19998831
    [No Abstract]   [Full Text] [Related]  

  • 47. Dabigatran etexilate in atrial fibrillation.
    Vora A
    J Assoc Physicians India; 2013 Dec; 61(12):900-2. PubMed ID: 24968547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
    Ezekowitz MD; Kent AP
    Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
    [No Abstract]   [Full Text] [Related]  

  • 49. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.
    Diener HC; Connolly SJ; Ezekowitz MD; Wallentin L; Reilly PA; Yang S; Xavier D; Di Pasquale G; Yusuf S;
    Lancet Neurol; 2010 Dec; 9(12):1157-1163. PubMed ID: 21059484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
    Siddiqui FM; Qureshi AI
    Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral anticoagulants for stroke prevention in atrial fibrillation.
    Senoo K; Lane DA; Lip GY
    Curr Probl Cardiol; 2014 Sep; 39(9):319-44. PubMed ID: 25194766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.
    Iyer V; Singh HS; Reiffel JA
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):237-47. PubMed ID: 22388002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
    Hankey GJ
    Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits and risks of thrombolytic, anticoagulant and antiplatelet therapies in atrial fibrillation.
    Marchant BG; Timmis AD
    Br J Hosp Med; 1993 Feb 3-16; 49(3):186-90. PubMed ID: 8439785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost of dabigatran for atrial fibrillation.
    Gage BF
    BMJ; 2011 Oct; 343():d6980. PubMed ID: 22042755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation.
    Aalbers J; Bryer A; Klug E
    Cardiovasc J Afr; 2010; 21(6):341. PubMed ID: 21135985
    [No Abstract]   [Full Text] [Related]  

  • 57. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
    Ahmad Y; Lip GY
    Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
    [No Abstract]   [Full Text] [Related]  

  • 58. Quality of anticoagulation control in atrial fibrillation.
    Lane DA; Lip GY
    Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
    [No Abstract]   [Full Text] [Related]  

  • 59. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
    Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Kansal AR; Zheng Y; Pokora T; Sorensen SV
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.